Anti-β2-glycoprotein I/HLA-DR Antibody and Adverse Obstetric Outcomes

Anti-β2-glycoprotein I/HLA-DR Antibody and Adverse Obstetric Outcomes

Anti-β2-glycoprotein I/HLA-DR (anti-β2GPI/HLA-DR) antibody has been reported to be associated with antiphospholipid syndrome and recurrent pregnancy loss (RPL). We conducted a prospective multicenter cross-sectional study aimed at evaluating whether the anti-β2GPI/HLA-DR antibody is associated with...

Full description

Bibliographic Details
Main Authors: Kenji Tanimura, Shigeru Saito, Sayaka Tsuda, Yosuke Ono, Hajime Ota, Shinichiro Wada, Masashi Deguchi, Mikiya Nakatsuka, Takeshi Nagamatsu, Tomoyuki Fujii, Gen Kobashi, Hisashi Arase, Hideto Yamada
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:International Journal of Molecular Sciences
Subjects:
antiphospholipid syndrome
autoantibody
β2-glycoprotein I
fetal growth restriction
HLA class II
hypertensive disorders of pregnancy
Online Access:https://www.mdpi.com/1422-0067/24/13/10958

Internet

https://www.mdpi.com/1422-0067/24/13/10958

Similar Items